Encoded Therapeutics’ gene therapy reduced seizures by 76% in children with Dravet syndrome, a severe form of childhood epilepsy and neurodevelopmental disorder.
Seventy-six percent is not a routine result in any epilepsy program. Dravet syndrome is one of the most treatment-resistant forms of childhood epilepsy; patients often cycle through multiple medications without gaining consistent control. For Encoded, this data point is the one that matters.
Encoded hasn’t shared trial size, patient age range, follow-up duration, or dosing details. The announcement gives one efficacy number: 76% seizure reduction in a pediatric Dravet population. That’s the complete data package.
The commercial story for rare pediatric gene therapy runs on premium economics. Orphan drug programs qualify for FDA incentives including extended market exclusivity and priority review eligibility. A 76% seizure reduction in a population this underserved gives Encoded a strong foundation for discussions with payers and regulators.
No PDUFA date, IND update, or regulatory filing timeline has been disclosed.
— Sarah Chen